Severe Immune thrombocytopenia induced by programmed death-1 monoclonal antibody:report of 3 cases
10.12173/j.issn.1008-049X.202405074
- VernacularTitle:程序性死亡受体1单抗诱发重度免疫性血小板减少(附3例报告)
- Author:
Zhenhua WANG
1
;
Feiyan YU
;
Fang LOU
;
Shu CHEN
;
Zhi XU
Author Information
1. 浙江省舟山市普陀区人民医院血液科(浙江舟山 316000)
- Keywords:
Programmed death-1;
Severe thrombocytopenia;
Diagnosis;
Treatment
- From:
China Pharmacist
2024;27(8):1459-1464
- CountryChina
- Language:Chinese
-
Abstract:
Objective To retrospectively explore the diagnosis and treatment of severe immune thrombocytopenia(SIT)induced by programmed death-1(PD-1)monoclonal antibody.Methods Three patients with SIT caused by PD-1 monoclonal antibody treatment at Putuo District People's Hospital,Zhoushan City,Zhejiang Province from March 2020 to October 2022 were selected,and the diagnosis and treatment process and disease outcome were analyzed.Results All three patients were diagnosed with malignant tumors after postoperative pathological examination,and SIT was induced after PD-1 monoclonal antibody treatment,of which one patient died,and two patients improved after the treatment.Conclusion PD-1 induced SIT often occurs after 12 weeks,and clinical diagnosis can be confirmed by combining patients'medication history,platelet antibodies,and bone marrow examination.In terms of treatment,combination therapy such as ordered reduction of hormones,thrombopoietin,and platelet receptor agonists can promote the recovery of the patient.In addition,if necessary,CD20 monoclonal antibody therapy can be applied to antagonize platelet antibodies.
